You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)

Article metrics

Article menu
Interstitial lung disease
Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)

 

Online download statistics by month:

Online download statistics by month: December 2021 to September 2024

AbstractFullPdf
Dec 2021545515
Jan 2022553550253
Feb 2022182189110
Mar 202222622377
Apr 2022205207119
May 202218018667
Jun 202215716269
Jul 202215115264
Aug 2022244240103
Sep 202222321792
Oct 202225426081
Nov 2022214209111
Dec 202217517750
Jan 2023243235117
Feb 2023308304114
Mar 2023224217119
Apr 202319419292
May 2023290291116
Jun 2023244236107
Jul 202317717287
Aug 2023202192112
Sep 2023266253107
Oct 2023310302114
Nov 2023239231113
Dec 202317916278
Jan 2024249239280
Feb 2024218194123
Mar 2024333331227
Apr 2024313305180
May 2024229230128
Jun 2024219199105
Jul 2024265242157
Aug 2024187175160
Sep 2024230207200
Total793777364047